Shopping Cart 0
Cart Subtotal
USD 0

Revance Therapeutics Inc (RVNC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Revance Therapeutics Inc (Revance Therapeutics) develops, manufactures and commercializes novel botulinum toxin products. The company's product candidate includes RT002, an injectable formulation of botulinum toxin type for the treatment of glabellar lines, cervical dystonia, and plantar fasciitis among others. It also provides RT001, a topical gel formulation of daxibotulinumtoxinA, which is designed to eliminate the use of needles. Revance Therapeutics develops products for multiple aesthetic and therapeutic applications. The company utilizes TransMTS platform technology for the development of its products. It offers products for dermatology, neurology, musculoskeletal disorders, urology and ophthalmology. Revance Therapeutics is headquartered in Newark, California, the US.

Revance Therapeutics Inc (RVNC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Revance Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Revance Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Revance Therapeutics Acquires Intellectual Property Portfolio of Botulinum Toxin from Botulinum Toxin Research Associates 12

Venture Financing 13

Revance Therapeutics Raises USD 10 Million In Venture Financing 13

Revance Therapeutics Raises USD 56 Million In Extended Series E Financing 14

Licensing Agreements 16

Mylan Enters into Licensing Agreement with Revance Therapeutics 16

Equity Offering 17

Revance Therapeutics Plans to Raise upto USD125 Million in Public Offering of Shares 17

Revance Therapeutics Raises USD167.1 Million in Public Offering of Shares 18

Revance Therapeutics Raises USD10.1 Million in Public Offering of Shares 20

Revance Therapeutics Raises USD134.6 Public Offering of Shares 21

Revance Therapeutics Raises USD10.8 Million in Public Offering of Shares 23

Revance Therapeutics Raises USD140.3 Million in Public Offering of Shares 24

Revance Therapeutics Completes IPO For USD 110.4 Million 26

Revance Therapeutics Inc-Key Competitors 28

Revance Therapeutics Inc-Key Employees 29

Revance Therapeutics Inc-Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Recent Developments 31

Financial Announcements 31

Nov 01, 2018: Revance releases third quarter 2018 results 31

Aug 02, 2018: Revance releases second quarter 2018 results 33

May 08, 2018: Revance Releases First Quarter 2018 Results 34

Feb 28, 2018: Revance Announces Fourth Quarter and Full Year 2017 Financial Results 35

Nov 02, 2017: Revance Releases Third Quarter 2017 Results 36

Aug 03, 2017: Revance Releases Second Quarter 2017 Results 37

May 09, 2017: Revance Releases First Quarter 2017 Results 38

Feb 27, 2017: Revance Releases Fourth Quarter and Full Year 2016 Results 39

Corporate Communications 41

Oct 11, 2018: Revance Therapeutics appoints Tobin C. Schilke as chief financial officer 41

May 09, 2018: Revance Therapeutics Announces Two Recent Additions to Its Management Team 42

May 01, 2018: Revance Therapeutics Appoints Caryn McDowell As SVP, General Counsel & Corporate Secretary 43

Sep 06, 2017: Revance Appoints Mark Foley to its Board of Directors 44

Aug 01, 2017: Revance Therapeutics Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer and President, Aesthetics & Therapeutics 45

Product News 46

01/12/2017: Revance Therapeutics Enters into USD 6.4M Settlement with City of Warren Police and Fire Retirement System 46

Clinical Trials 47

Jun 05, 2017: Revance Reports Additional Positive Week 24 Efficacy Results from RT002 Injectable Phase 2 Cervical Dystonia Trial 47

May 18, 2017: Revance Announces Positive Top-Line 24-Week Duration of Effect Results in All Three Cohorts in RT002 Injectable Phase 2 Cervical Dystonia Trial 49

May 01, 2017: Revance Provides Update on Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis 51

Mar 07, 2017: Revance Completes Enrollment in Phase 3 Pivotal Trials of RT002 Injectable for the Treatment of Glabellar (Frown) Lines 52

Mar 03, 2017: Revance Announces BELMONT Phase 2 Clinical Data to Be Presented at the 2017 American Academy of Dermatology (AAD) Annual Meeting 53

Jan 26, 2017: BELMONT Phase 2 Clinical Data to be Presented at IMCAS World Congress 2017 54

Jan 18, 2017: Revance Presents Clinical Data for RT002 Injectable at TOXINS 2017 55

Jan 05, 2017: Revance Provides Clinical Milestones and Financial Outlook for 2017 56

Appendix 57

Methodology 57

About GlobalData 57

Contact Us 57

Disclaimer 57


List Of Figure

List of Figures

Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Revance Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Revance Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Revance Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Revance Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Revance Therapeutics Acquires Intellectual Property Portfolio of Botulinum Toxin from Botulinum Toxin Research Associates 12

Revance Therapeutics Raises USD 10 Million In Venture Financing 13

Revance Therapeutics Raises USD 56 Million In Extended Series E Financing 14

Mylan Enters into Licensing Agreement with Revance Therapeutics 16

Revance Therapeutics Plans to Raise upto USD125 Million in Public Offering of Shares 17

Revance Therapeutics Raises USD167.1 Million in Public Offering of Shares 18

Revance Therapeutics Raises USD10.1 Million in Public Offering of Shares 20

Revance Therapeutics Raises USD134.6 Public Offering of Shares 21

Revance Therapeutics Raises USD10.8 Million in Public Offering of Shares 23

Revance Therapeutics Raises USD140.3 Million in Public Offering of Shares 24

Revance Therapeutics Completes IPO For USD 110.4 Million 26

Revance Therapeutics Inc, Key Competitors 28

Revance Therapeutics Inc, Key Employees 29

Revance Therapeutics Inc, Subsidiaries 30

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Revance Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Summary

Revance Therapeutics Inc (Revance Therapeutics) develops, manufactures and commercializes novel botulinum toxin products. The company's product candidate includes RT002, an injectable formulation of botulinum toxin type for the treatment of glabellar lines, cervical dystonia, and plantar fasciitis among others. It also provides RT001, a topical gel formulation of daxibotulinumtoxinA, which is designed to eliminate the use of needles. Revance Therapeutics develops products for multiple aesthetic and therapeutic applications. The company utilizes TransMTS platform technology for the development of its products. It offers products for dermatology, neurology, musculoskeletal disorders, urology and ophthalmology. Revance Therapeutics is headquartered in Newark, California, the US.

Revance Therapeutics Inc (RVNC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Revance Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Revance Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Revance Therapeutics Acquires Intellectual Property Portfolio of Botulinum Toxin from Botulinum Toxin Research Associates 12

Venture Financing 13

Revance Therapeutics Raises USD 10 Million In Venture Financing 13

Revance Therapeutics Raises USD 56 Million In Extended Series E Financing 14

Licensing Agreements 16

Mylan Enters into Licensing Agreement with Revance Therapeutics 16

Equity Offering 17

Revance Therapeutics Plans to Raise upto USD125 Million in Public Offering of Shares 17

Revance Therapeutics Raises USD167.1 Million in Public Offering of Shares 18

Revance Therapeutics Raises USD10.1 Million in Public Offering of Shares 20

Revance Therapeutics Raises USD134.6 Public Offering of Shares 21

Revance Therapeutics Raises USD10.8 Million in Public Offering of Shares 23

Revance Therapeutics Raises USD140.3 Million in Public Offering of Shares 24

Revance Therapeutics Completes IPO For USD 110.4 Million 26

Revance Therapeutics Inc-Key Competitors 28

Revance Therapeutics Inc-Key Employees 29

Revance Therapeutics Inc-Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Recent Developments 31

Financial Announcements 31

Nov 01, 2018: Revance releases third quarter 2018 results 31

Aug 02, 2018: Revance releases second quarter 2018 results 33

May 08, 2018: Revance Releases First Quarter 2018 Results 34

Feb 28, 2018: Revance Announces Fourth Quarter and Full Year 2017 Financial Results 35

Nov 02, 2017: Revance Releases Third Quarter 2017 Results 36

Aug 03, 2017: Revance Releases Second Quarter 2017 Results 37

May 09, 2017: Revance Releases First Quarter 2017 Results 38

Feb 27, 2017: Revance Releases Fourth Quarter and Full Year 2016 Results 39

Corporate Communications 41

Oct 11, 2018: Revance Therapeutics appoints Tobin C. Schilke as chief financial officer 41

May 09, 2018: Revance Therapeutics Announces Two Recent Additions to Its Management Team 42

May 01, 2018: Revance Therapeutics Appoints Caryn McDowell As SVP, General Counsel & Corporate Secretary 43

Sep 06, 2017: Revance Appoints Mark Foley to its Board of Directors 44

Aug 01, 2017: Revance Therapeutics Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer and President, Aesthetics & Therapeutics 45

Product News 46

01/12/2017: Revance Therapeutics Enters into USD 6.4M Settlement with City of Warren Police and Fire Retirement System 46

Clinical Trials 47

Jun 05, 2017: Revance Reports Additional Positive Week 24 Efficacy Results from RT002 Injectable Phase 2 Cervical Dystonia Trial 47

May 18, 2017: Revance Announces Positive Top-Line 24-Week Duration of Effect Results in All Three Cohorts in RT002 Injectable Phase 2 Cervical Dystonia Trial 49

May 01, 2017: Revance Provides Update on Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis 51

Mar 07, 2017: Revance Completes Enrollment in Phase 3 Pivotal Trials of RT002 Injectable for the Treatment of Glabellar (Frown) Lines 52

Mar 03, 2017: Revance Announces BELMONT Phase 2 Clinical Data to Be Presented at the 2017 American Academy of Dermatology (AAD) Annual Meeting 53

Jan 26, 2017: BELMONT Phase 2 Clinical Data to be Presented at IMCAS World Congress 2017 54

Jan 18, 2017: Revance Presents Clinical Data for RT002 Injectable at TOXINS 2017 55

Jan 05, 2017: Revance Provides Clinical Milestones and Financial Outlook for 2017 56

Appendix 57

Methodology 57

About GlobalData 57

Contact Us 57

Disclaimer 57


List Of Figure

List of Figures

Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Revance Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Revance Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Revance Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Revance Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Revance Therapeutics Acquires Intellectual Property Portfolio of Botulinum Toxin from Botulinum Toxin Research Associates 12

Revance Therapeutics Raises USD 10 Million In Venture Financing 13

Revance Therapeutics Raises USD 56 Million In Extended Series E Financing 14

Mylan Enters into Licensing Agreement with Revance Therapeutics 16

Revance Therapeutics Plans to Raise upto USD125 Million in Public Offering of Shares 17

Revance Therapeutics Raises USD167.1 Million in Public Offering of Shares 18

Revance Therapeutics Raises USD10.1 Million in Public Offering of Shares 20

Revance Therapeutics Raises USD134.6 Public Offering of Shares 21

Revance Therapeutics Raises USD10.8 Million in Public Offering of Shares 23

Revance Therapeutics Raises USD140.3 Million in Public Offering of Shares 24

Revance Therapeutics Completes IPO For USD 110.4 Million 26

Revance Therapeutics Inc, Key Competitors 28

Revance Therapeutics Inc, Key Employees 29

Revance Therapeutics Inc, Subsidiaries 30

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Revance Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

chat_bubbleLet's Chat